A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors

被引:1
|
作者
Mehra, Anuradha [1 ]
Sangwan, Rekha [1 ]
机构
[1] Lovely Profess Univ, Sch Pharmaceut Sci, Dept Pharmaceut Chem, Jalandhar Delhi GT Rd NH 1, Phagwara 144411, Punjab, India
关键词
FGFR; anticancer; SAR; potency; heterocyclic; angiogenesis; FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; BIOLOGICAL EVALUATION; KINASE INHIBITOR; CH5183284/DEBIO; 1347; SELECTIVE INHIBITOR; PHASE-I; DESIGN; POTENT; DISCOVERY;
D O I
10.2174/0118715206318833240819031953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FGFR have been demonstrated to perform a crucial role in biological processes but their over-expression has been perceived as the operator component in the occurrence and progression of different types of carcinoma. Out of all the interest around cancer, FGFR inhibitors have assembled pace over the past few years. Therefore, FGFR inhibitors are one of the main fundamental tools to reverse drug resistance, tumor growth, and angiogenesis. Currently, many FGFR inhibitors are under the development stage or have been developed. Due to great demand and hotspots, different pharmacophores were approached to access structurally diverse FGFR inhibitors. Here, we have selected to present several representative examples such as Naphthyl, Pyrimidine, Pyridazine, Indole, and Quinoline derivatives that illustrate the diversity and advances of FGFR inhibitors in medicinal chemistry. This review focuses on the SAR study of FGFR inhibitors last five years which will be a great future scope that influences the medicinal chemist to work towards more achievements in this area.
引用
收藏
页码:2 / 23
页数:22
相关论文
共 50 条
  • [2] Treatment of Cancer: Need for Paradigm Shift
    Ponnuraj, Kannan Thirumulu
    ARCHIVES OF OROFACIAL SCIENCE, 2019, 14 (02): : 75 - 76
  • [3] Cancer immunotherapy: a paradigm shift for prostate cancer treatment
    Dev Karan
    Jeffrey M. Holzbeierlein
    Peter Van Veldhuizen
    J. Brantley Thrasher
    Nature Reviews Urology, 2012, 9 : 376 - 385
  • [4] Cancer immunotherapy: a paradigm shift for prostate cancer treatment
    Karan, Dev
    Holzbeierlein, Jeffrey M.
    Van Veldhuizen, Peter
    Thrasher, J. Brantley
    NATURE REVIEWS UROLOGY, 2012, 9 (07) : 376 - 385
  • [5] Nanotherapeutics in autophagy: a paradigm shift in cancer treatment
    Shloka Negi
    Aiswarya Chaudhuri
    Dulla Naveen Kumar
    Deepa Dehari
    Sanjay Singh
    Ashish Kumar Agrawal
    Drug Delivery and Translational Research, 2022, 12 : 2589 - 2612
  • [6] Nanotherapeutics in autophagy: a paradigm shift in cancer treatment
    Negi, Shloka
    Chaudhuri, Aiswarya
    Kumar, Dulla Naveen
    Dehari, Deepa
    Singh, Sanjay
    Agrawal, Ashish Kumar
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2022, 12 (11) : 2589 - 2612
  • [7] Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer
    Oshima, Kotoe
    Yamazaki, Kentaro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (11) : 1442 - 1450
  • [8] Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer
    Kotoe Oshima
    Kentaro Yamazaki
    International Journal of Clinical Oncology, 2023, 28 : 1442 - 1450
  • [9] Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment
    Peng, Yan
    Zhang, Pengfei
    Mei, Wuxuan
    Zeng, Changchun
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 267
  • [10] Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment
    Barzi, Afsaneh
    Thara, Eddie
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (09) : 1319 - 1332